To determine the impact of low volume high-intensity interval training (LVHIIT) and continuous low to moderate-intensity exercise training (CLMIT) on cardiovascular disease (CVD) risk and health outcomes in cancer survivors.
Sedentary cancer survivors (n= 75, aged 51 ± 12 year) within 24 months of diagnosis, were randomised into three groups for 12 wk of LVHIIT (n= 25), CLMIT (n= 25) or control group (n= 25). The exercise intervention involved 36 sessions (three sessions per week). The LVHIIT group performed 7 x 30 s intervals (≥ 85% predicted maximal heart rate) with a 60 s rest between intervals, and the CLMIT group performed continuous aerobic training for 20 min (≤ 55% predicted maximal heart rate) on a stationary bike. Outcome variables were measured at baseline and at 12 weeks and analysed using a 3 x 2 (group x time) repeated measures ANCOVA to evaluate main and interaction effects.
Significant improvements (time) were observed for seven of the 22 variables (ES 0.35-0.97,P≤ 0.05). There was an interaction effect (P< 0.01) after 12 wk in the LVHIIT group for six-minute walk test (P< 0.01;d= 0.97; 95%CI: 0.36, 1.56; large), sit to stand test (P< 0.01;d= -0.83; 95%CI: -1.40, -0.22; large ) and waist circumference reduction (P= 0.01;d= -0.48; 95%CI: -1.10, 0.10; medium). An interaction effect (P< 0.01) was also observed for quality of life in both the LVHIIT (d= 1.11; 95%CI: 0.50, 1.72; large) and CLMIT (d= 0.57; 95%CI: -0.00, 1.20; moderate) compared with the control group (d= -0.15; 95%CI: -0.95, 0.65; trivial).
Low-volume high-intensity training shows promise as an effective exercise prescription within the cancer population, showing greater improvements in cardio-respiratory fitness, lower body strength and waist circumference compared with traditional CLMIT and control groups. Both LVHIIT and CLMIT improved quality of life. A proposed benefit of LVHIIT is the short duration (3 min) of exercise required, which may entice more cancer survivors to participate in exercise, improving health outcomes and lowing the risk of CVD.
Pharmacology, Toxicology and Pharmaceutical Science
2
2%
Agricultural and Biological Sciences
1
1%
Other
8
8%
Unknown
43
43%
Attention Score in Context
Attention Score in Context
This research output has an Altmetric Attention Score of 15. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 May 2021.
All research outputs
#3,132,804
of 33,825,399 outputs
Outputs from World Journal of Clinical Oncology
#47
of 438 outputs
Outputs of similar age
#55,632
of 495,954 outputs
Outputs of similar age from World Journal of Clinical Oncology
#1
of 2 outputs
Altmetric has tracked 33,825,399 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 90th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 438 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 7.5. This one has done well, scoring higher than 89% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 495,954 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 88% of its contemporaries.
We're also able to compare this research output to 2 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them
